S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Exelixis Announces Presentation of Updated Phase 1b Data for Cobimetinib (GDC-0973/XL518) in Combination with Vemurafenib at ECC 2013 (2013/9/28)|
|AstraZeneca Initiates Phase 3 Clinical Trial For Selumetinib In Non-Small Cell Lung Cancer (2013/10/22)|
|Exelixis Announces Full Patient Enrollment Target Has Been Achieved for COMET-1 (2013/9/26)|
|Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 And Announces ARRY-520 Development Strategy (2013/10/31)|
|Astex Pharmaceuticals Announces First Data Showing Early Combination Treatment of HSP90 Inhibitor AT13387 With Targeted Agents Delays Emergence of Resistance in Preclinical Models (2013/7/22)|
|Threshold Pharmaceuticals Initiates Phase 2 Study of TH-302 in Patients With Advanced Melanoma (2013/8/8)|
|Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2013 ()|
|Array BioPharma To Present Clinical Data At The 2013 ASH Annual Meeting On ARRY-520 For Multiple Myeloma And ARRY-614 For Myelodysplastic Syndromes (2013/11/7)|
|Array BioPharma To Present At The Jefferies 2013 Global Healthcare And Piper Jaffray 25th Annual Healthcare Conferences (2013/11/11)|
Click above to view more mutual fund data and stats for mek - Metals Creek Resources Corp..